GSK’s ViiV Expands Licensing Deal to Increase Access to Long-Acting Injectable HIV Treatment

ViiV Healthcare, majority-owned by GSK, has extended its voluntary licensing agreement with the Medicines Patent Pool (MPP) to include patents for the use of cabotegravir in long-acting (LA) injectable HIV treatment regimens1.

This expanded agreement now allows generic manufacturers to develop, manufacture, and supply generic long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries, including all least-developed, low-income, lower middle-income, and Sub-Saharan African countries, as well as countries without ViiV patent rights for cabotegravir1.

Previously, the voluntary license covered only cabotegravir for HIV pre-exposure prophylaxis (PrEP); the extension now enables generic access for treatment in addition to prevention1.

The agreement follows updated World Health Organization recommendations endorsing long-acting injectable cabotegravir plus rilpivirine as an option for HIV treatment1.

Implementation of the expanded license is subject to regulatory approvals for the generic products1.

Sources:

1. https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-extends-voluntary-licensing-agreement-with-medicines-patent-pool-to-enable-access-to-innovative-long-acting-injectable-hiv-treatment/